NCT05831176: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 10 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05831176 |
|---|---|
| Title | A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 3, 2023 |
| Completion date | Feb. 18, 2026 |
| Required reporting date | Feb. 18, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |